Melanoma: Molecular Oncology Tumor Boards

This free case-based activity includes a crowd-sourced discussion of a A 63-year-old female who developed rectal bleeding from a prominent rectal mass which was proven to be melanoma by biopsy. The tumor was deemed initially unresectable and the patient started with Ipi/Nivo x2 cycles. The tumor shrunk by 30% but treatment was discontinued due to Grade 3 diarrhea. The patient was referred to an expert surgical center where an abdominal perineal resection of the tumor was conducted. Pathology showed residual viable tumor cells and all 20 resected lymph nodes were tumor-free. Paired sequencing of 500 cancer related genes in tumor and normal tissue was performed. Six months later, the patient developed multiple new nodules in the lung biopsy proven to be recurrent melanoma.

Originally posted on a forum in the ASCO Connection, users now have the opportunity to claim CME, completion, or participation certificates for completing this activity.

Learning Objectives:
1.  Analyze mucosal melanomas as distinct melanoma subtypes with worse survival outcomes and lower treatment response rates in the metastatic setting.
2.  Define common genetic alterations in mucosal melanoma.
3.  Evaluate how the response to KIT-directed therapy varies dependent on the type of KIT alterations.

Continuing Education Credit

1 Credit/Point is available for participation in this course. Certificate and credit types available include:

  • AMA PRA Category 1 Credits
  • ABIM MOC Points
  • CNE Contact Hours
  • CPE Credits
  • Certificate of Participation may be used to confer credit; however, all final decisions regarding the awarding of credits will be made by the licensing organization to which the credits are submitted.
  • Certificate of Completion may be used to document participation, but no credit will be conferred.

Important Note: This course expires on December 20, 2020. Participants must complete all necessary course components by this date to receive credit